CoChat

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Open access

Abstract

Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01556-7

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 IRRs and 95% CIs for neurological outcomes following ChAdOx1nCoV-19 vaccination, BNT162b2 vaccination and positive SARS-CoV-2 test. The IRRs are presented for pre-defined risk periods (0, 1–7, 8–14, 15–21 and 22–28 days) after each exposure and for the pre-risk period (28 days prior to exposure) and computed using a population of n = 32,553,534 vaccinated individuals. The horizontal bold line indicates an IRR of 1.
Fig. 1 IRRs and 95% CIs for neurological outcomes following ChAdOx1nCoV-19 vaccination, BNT162b2 vaccination and positive SARS-CoV-2 test. The IRRs are presented for pre-defined risk periods (0, 1–7, 8–14, 15–21 and 22–28 days) after each exposure and for the pre-risk period (28 days prior to exposure) and computed using a population of n = 32,553,534 vaccinated individuals. The horizontal bold line indicates an IRR of 1.CC BY · PubMed Central
Fig. 2 Schematic presentation of the SCCS study design. Each patient is followed from the index date to the study end date and is censored if death occurred or if they had a second dose of vaccine. Risk intervals (0, 1–7, 8–14, 15–21 and 22–28 days after exposure), the pre-risk interval (the 28 days prior to exposure) and the baseline periods (from study start to 29 days before exposure, and from 29 days after exposure to study end) are shown.
Fig. 2 Schematic presentation of the SCCS study design. Each patient is followed from the index date to the study end date and is censored if death occurred or if they had a second dose of vaccine. Risk intervals (0, 1–7, 8–14, 15–21 and 22–28 days after exposure), the pre-risk interval (the 28 days prior to exposure) and the baseline periods (from study start to 29 days before exposure, and from 29 days after exposure to study end) are shown.CC BY · PubMed Central
Extended Data Fig. 1 Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to ChAdOx1nCoV-19 vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to ChAdOx1nCoV-19 vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.
Extended Data Fig. 1 Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to ChAdOx1nCoV-19 vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to ChAdOx1nCoV-19 vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.CC BY · PubMed Central
Extended Data Fig. 2 Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to BNT162b2 mRNA vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to BNT162b2 mRNA vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.
Extended Data Fig. 2 Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to BNT162b2 mRNA vaccine. Incidence rate ratios (IRR 95% CI) for single outcomes in pre-defined risk periods immediately before and after exposure to BNT162b2 mRNA vaccine, adjusted for calendar time from 1 December 2020 to 31 May 2021 computed using a population of size n = 32,553,534 vaccinated individuals. Comparisons between different sensitivity analyses (cells with < 5 are suppressed). Horizontal bold line indicates 1.CC BY · PubMed Central
Extended Data Fig. 3 Data flow chart. Flowchart of data used in this study showing how data from National Immunisation Management System (NIMS), Second Generation Surveillance System (SGSS), Hospital Episode Statistics (HES) and Office of National Statistic (ONS) were used to obtain information about vaccinations, SARS-CoV-2 test results, and hospital admissions for neurological outcomes and deaths, respectively.
Extended Data Fig. 3 Data flow chart. Flowchart of data used in this study showing how data from National Immunisation Management System (NIMS), Second Generation Surveillance System (SGSS), Hospital Episode Statistics (HES) and Office of National Statistic (ONS) were used to obtain information about vaccinations, SARS-CoV-2 test results, and hospital admissions for neurological outcomes and deaths, respectively.CC BY · PubMed Central
Extended Data Fig. 4 Number of hospital admissions or deaths for each outcome in the baseline and in the exposed set by week. Number of hospital admissions or deaths for each outcome in the baseline and in the exposed set by week from 1 December 2020 to 31 May 2021 (n = 32,553,534).
Extended Data Fig. 4 Number of hospital admissions or deaths for each outcome in the baseline and in the exposed set by week. Number of hospital admissions or deaths for each outcome in the baseline and in the exposed set by week from 1 December 2020 to 31 May 2021 (n = 32,553,534).CC BY · PubMed Central
Extended Data Fig. 5 Number of hospital admissions or deaths for each outcome prior and post each vaccine. Number of hospital admissions or deaths for each outcome prior and post each vaccine from 1 December 2020 to 31 May 2021 (n = 32,553,534). Red line: vaccine date; green line: 28 days prior vaccine; black line: 28 days post vaccine.
Extended Data Fig. 5 Number of hospital admissions or deaths for each outcome prior and post each vaccine. Number of hospital admissions or deaths for each outcome prior and post each vaccine from 1 December 2020 to 31 May 2021 (n = 32,553,534). Red line: vaccine date; green line: 28 days prior vaccine; black line: 28 days post vaccine.CC BY · PubMed Central
Extended Data Fig. 6 Time between end of study or censored date and date of hospital admission or deaths for each outcome. Time between end of study or censored date and date of hospital admission or deaths for each outcome from 1 December 2020 to 31 May 2021 (n = 32,553,534).
Extended Data Fig. 6 Time between end of study or censored date and date of hospital admission or deaths for each outcome. Time between end of study or censored date and date of hospital admission or deaths for each outcome from 1 December 2020 to 31 May 2021 (n = 32,553,534).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 425

Metadata

Authors
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., Khunti, K., Watkinson, P., Coupland, C. A. C., Doidge, J., Harrison, D. A., Ravanan, R., Sheikh, A., Robertson, C., & Hippisley-Cox, J.
Affiliations
  • University of Oxford (GB)
  • Centre for Human Genetics (GB)
  • University of Strathclyde (GB)
  • MRC/CSO Social and Public Health Sciences Unit (GB)
  • University of Glasgow (GB)
  • UK Dementia Research Institute (GB)
  • University of Leicester (GB)
  • University of Nottingham (GB)
  • London School of Hygiene & Tropical Medicine (GB)
Venue
Nature Medicine
Published
2021-10-25
Volume
27
Issue
12
Pages
2144-2153
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3210722677
Cited by
394
References
25
Citations by year
2026: 27 · 2025: 38 · 2024: 77 · 2023: 89 · 2022: 155 · 2021: 8
FWCI
26.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (acceptedVersion, cc-by)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
Funders
  • U.S. Department of Veterans Affairs (PEC 13‐001)
  • Wellcome Trust (215621/Z/19/Z)
  • UK Research and Innovation (SCAF/15/02, MC_UU_00022/2, MC_PC_20029)
  • Cancer Research UK (A18085, C5255, C5255/A18085, 204826/Z/16/Z)
  • National Institute for Health and Care Research (CL-2019-13-001, 13001, MC_UU_00022/2, C5255/A18085, SCAF/15/02)
  • Academy of Medical Sciences (AMS-SGCL7-Hunt)
  • University of Oxford (204826/Z/16/Z)
  • Medical Research Council (MC_UU_00022/2, SPHSU17, MC_UU_00022, MC_PC_20029, SCAF/15/02)
  • Health Data Research UK (MC_PC_20029)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 vaccines, neurological complications, Guillain-Barré syndrome, Bell's palsy, hemorrhagic stroke, BNT162b2, COVID-19 pandemic, vaccine safety
MeSH terms
Hemorrhagic Stroke, COVID-19, SARS-CoV-2, BNT162 Vaccine, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, England, Female, Hospitalization, Humans, Male, Middle Aged, Nervous System Diseases, Scotland, Guillain-Barre Syndrome, Bell Palsy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1038/s41591-021-01556-7
The paper
Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., Khunti, K., Watkinson, P., Coupland, C. A. C., Doidge, J., Harrison, D. A., Ravanan, R., Sheikh, A., Robertson, C., & Hippisley-Cox, J. (2021). Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01556-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.